Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,361 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (646)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04203641 | L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 28 | Helix BioPharma CorporationINDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT05251233 | Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy | terminated | Phase 2 | 56 | Washington University School of MedicineOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT05757492 | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors | terminated | Phase 1 | 22 | Coherus Oncology, Inc.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT05448677 | Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma(ABE-LIVER) | terminated | Phase 2 | 3 | University Hospital, GrenobleOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT05565794 | Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements | terminated | Phase 2 | 2 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT05737706 | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | terminated | Phase 1 | 63 | Mirati Therapeutics Inc.INDUSTRY | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | terminated | Phase 2 | 54 | Elevation OncologyINDUSTRY | 4 | Apr 3, 2025 | clinicaltrials |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | terminated | Phase 1 / Phase 2 | 222 | Kymab LimitedINDUSTRY | 6 | Apr 2, 2025 | clinicaltrials |
| NCT05494866 | A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma(IntenSify) | terminated | Phase 1 | 6 | German Cancer Research CenterOTHER | 1 | Mar 25, 2025 | clinicaltrials |
| NCT03889093 | Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System | terminated | N/A | 14 | University of MinnesotaOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT04866836 | A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors | terminated | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04629339 | Study of INCB086550 in Select Solid Tumors | terminated | Phase 2 | 16 | Incyte CorporationINDUSTRY | 5 | Mar 13, 2025 | clinicaltrials |
| NCT05137899 | Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy(ADVANCE HCC) | terminated | Phase 2 | 1 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT05770882 | Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC) | terminated | Phase 1 / Phase 2 | 7 | Great Novel Therapeutics Biotech & Medicals CorporationINDUSTRY | 1 | Mar 11, 2025 | clinicaltrials |
| NCT03812289 | Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer | terminated | N/A | 9 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT00881621 | Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer | terminated | Phase 2 | 17 | Georgetown UniversityOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06848556 | Evaluate the Effect of Tirazamine on Primary Liver Cancer. | terminated | Phase 1 / Phase 2 | 16 | Zhejiang Raygene Pharmaceuticals Co., LtdINDUSTRY | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04709380 | Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT | terminated | Phase 3 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT05909995 | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors | terminated | Phase 1 | 8 | Incyte CorporationINDUSTRY | 3 | Feb 18, 2025 | clinicaltrials |
| NCT03822936 | Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma(PIOPPO) | terminated | Phase 2 | 30 | CNAO National Center of Oncological HadrontherapyOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT01205828 | ABT-888 and Temozolomide for Liver Cancer | terminated | Phase 2 | 16 | Georgetown UniversityOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT05631574 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer | terminated | Phase 1 | 13 | Biomea Fusion Inc.INDUSTRY | 2 | Feb 7, 2025 | clinicaltrials |
| NCT05497453 | A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene(MYCHELANGELO I) | terminated | Phase 1 / Phase 2 | 24 | Omega TherapeuticsINDUSTRY | 5 | Feb 3, 2025 | clinicaltrials |
| NCT03736720 | Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin | terminated | Phase 2 | 11 | Roswell Park Cancer InstituteOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT05845502 | Single-arm, Open-label Clinical Study of SZ003 in the Treatment of Advanced Hepatocellular Carcinoma | terminated | N/A | 8 | Shantou University Medical CollegeOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT05776875 | Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC | terminated | Phase 2 | 3 | Yale UniversityOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT04066660 | Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC) | terminated | N/A | 87 | Hi-Q Marine Biotech International, Ltd.INDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT05653427 | A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma | terminated | Phase 2 | 18 | Janssen Research & Development, LLCINDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT02671890 | Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer | terminated | Phase 1 | 16 | Mayo ClinicOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT05546411 | A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer | terminated | Phase 2 | 8 | Kimberly Perez, MDOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT02878473 | Liver Transplantation for Early Intrahepatic Cholangiocarcinoma(LT for iCCA) | terminated | Phase 2 | 2 | University Health Network, TorontoOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | terminated | Phase 1 | 127 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 13, 2024 | clinicaltrials |
| NCT04136769 | Preoperative/Neoadjuvant Therapy and Vascular Debranching Followed by Resection for Locally Advanced Pancreatic Cancer(PREVADER) | terminated | N/A | 3 | Ulrich Ronellenfitsch, MDOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT03145558 | TATE Versus TACE in Intermediate Stage HCC(TATE) | terminated | Phase 2 | 6 | Teclison Ltd.INDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT01101906 | A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC | terminated | Phase 2 | 23 | Astellas Pharma IncINDUSTRY | 10 | Nov 20, 2024 | clinicaltrials |
| NCT02512692 | Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma | terminated | N/A | 6 | Medical University of South CarolinaOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT01318642 | Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas | terminated | Phase 2 | 10 | NantBioScience, Inc.INDUSTRY | 13 | Nov 8, 2024 | clinicaltrials |
| NCT04989218 | Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)(ICC) | terminated | Phase 1 / Phase 2 | 1 | University of Alabama at BirminghamOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | terminated | Phase 1 | 15 | Molecular Templates, Inc.INDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT03592264 | A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 68 | OBI Pharma, IncINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04003896 | A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma | terminated | Phase 2 | 4 | Milton S. Hershey Medical CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT04536077 | Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients | terminated | Phase 2 | 16 | Washington University School of MedicineOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | terminated | Phase 1 / Phase 2 | 13 | BioNTech SEINDUSTRY | 2 | Oct 2, 2024 | clinicaltrials |
| NCT00667628 | Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma | terminated | Phase 2 | 54 | Taiho Oncology, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT00687596 | Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy | terminated | Phase 2 | 52 | Taiho Oncology, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03960008 | Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant(SBRTvsTACE) | terminated | Phase 3 | 9 | Lahey ClinicOTHER | 2 | Aug 28, 2024 | clinicaltrials |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Tango Therapeutics, Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05352542 | GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma | terminated | Phase 1 | 10 | jianming xuOTHER | 1 | Aug 9, 2024 | clinicaltrials |
Data updated 23 days agoSource updated May 6, 2025source: clinicaltrials